Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.79 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.79 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.79 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.64 |
| ▸ | FAAH | O00519 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | CNR2 | P34972 | 1/20 | 0.64 |
| ▸ | SELP | P16109 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13481433 | 1.00 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL29934740 | 1.00 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL29934675 | 1.00 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL29934864 | 1.00 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL29935123 | 1.00 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL29934264 | 1.00 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL2578664 | 1.00 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL29934263 | 1.00 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL29934738 | 1.00 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL29651586 | 0.99 | PRKCA (0.77) | PRKCAPRKCEPRKCQPRKCDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132906-A1 | FOCUSED ULTRASOUND THERMAL ABLATION WITH THERMAL ENHANCERS | BRACCO SUISSE SA (CH) | 2025-06-26 | — | — | WO | claimed |
| WO-2025021286-A1 | A DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-01-30 | — | — | WO | claimed |
| EP-0995430-A2 | Use of diacylolycerols for enhancing the barrier function of the skin | Beiersdorf Aktiengesellschaft (DE) | 2000-04-26 | — | — | EP | claimed |
| EP-0655907-B1 | USE OF DIACYLOLYCEROLS FOR INCREASING THE MELANIN CONTENT IN MELANOCYTES | UNIV BOSTON (US) | 1999-04-28 | — | — | EP | claimed |
| WO-1996009810-A1 | METHODS FOR ENHANCING MELANIN SYNTHESIS IN MELANOCYTES USING DIACYLGLYCEROLS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 1996-04-04 | — | — | WO | claimed |
| US-5051448-A | Gamma-aminobutyric acid derivatives that can cross brain barriers for a neurotransmitter | THE MCLEAN HOSPITAL CORPORATION (US) | 1991-09-24 | — | — | US | claimed |
| US-4845028-A | 1,2-DIGLYCERIDE, NONIONIC SURFACTANT | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-07-04 | — | — | US | claimed |
| EP-0133795-B1 | GABA ESTERS AND GABA ANALOGUE ESTERS | THE McLEAN HOSPITAL CORPORATION (US) | 1989-01-18 | — | — | EP | claimed |
| EP-0133795-A1 | Gaba esters and gaba analogue esters | THE McLEAN HOSPITAL CORPORATION (US) | 1985-03-06 | — | — | EP | claimed |
| WO-1985000520-A1 | GABA ESTERS AND GABA ANALOGUE ESTERS | THE MCLEAN HOSPITAL CORPORATION (US) | 1985-02-14 | — | — | WO | claimed |
| EP-4746853-A1 | A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025021835-A9 | A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-11-06 | — | — | WO | disclosed |
| WO-2025132906-A1 | FOCUSED ULTRASOUND THERMAL ABLATION WITH THERMAL ENHANCERS | BRACCO SUISSE SA (CH) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025021835-A1 | A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-01-30 | — | — | WO | disclosed |
| US-20240226287-A1 | NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-07-11 | — | — | US | disclosed |
| US-5352440-A | Methods for increasing melanin content in melanocytes using diacylglycerols and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 1994-10-04 | — | — | US | disclosed |
| EP-0373195-A1 | COMPOSITION FOR INCREASING MELANIN CONTENT OF MELANOCYTES IN-VIVO AND IN-VITRO AND METHODS FOR THE IN-VITRO USE THEREOF. | TUFTS COLLEGE (US) | 1990-06-20 | — | — | EP | disclosed |
| EP-0373195-A4 | COMPOSITION FOR INCREASING MELANIN CONTENT OF MELANOCYTES IN-VIVO AND IN-VITRO AND METHODS FOR THE IN-VITRO USE THEREOF. | TUFTS COLLEGE (US) | 1990-05-14 | — | — | EP | disclosed |
| WO-1989009258-A1 | METHODS FOR INCREASING MELANIN CONTENT AND FOR INDUCING MELANOCYTE PROLIFERATION IN-VIVO AND IN-VITRO | TRUSTEES OF TUFTS COLLEGE (US) | 1989-10-05 | — | — | WO | disclosed |
| US-4845028-A | 1,2-DIGLYCERIDE, NONIONIC SURFACTANT | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226287-A1 | NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING THE SAME | HDLBP, LRAT, CETP | PRKCA 3535/4885PRKCE 3278/4885PRKCQ 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.